# KKR Genetic Disorder L.P. (BBIO) — capital_raise [pending]
Source: sec.gov · situation sit_75347589fc6c5482746f · public 9102887913893233732 · retrieved 2026-08-20T13:18:45.740Z

## Overview
BridgeBio Pharma, Inc. is a pharmaceutical company engaged in the development of treatments for genetic disorders.

KKR Genetic Disorder L.P. sold 5,000,000 shares of common stock of BridgeBio Pharma, Inc. at a net price of $77.415 per share through an underwriting agreement with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC, and KKR Capital Markets LLC as representatives. The offering closed on August 17, 2026. Following the offering, KKR Genetic Disorder L.P. ceased to be a beneficial owner of more than 5% of BridgeBio's common stock, making this an exit filing.

## Terms
- Counterparty: William Blair & Company, L.L.C., Goldman Sachs & Co. LLC, KKR Capital Markets LLC (underwriters) · Consideration: cash · Price/share: $77.415

## Key dates
- Announced 2026-08-17 · Expected close 2026-08-17

## Timeline
- 2026-08-17 · 8-K (0001140361-26-033282): 8-K - BridgeBio Pharma, Inc. — *BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions.* On August 13, 2026, BridgeBio Pharma, Inc. and KKR Genetic Disorder L.P. entered into an underwriting agreement with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC, and KKR Capital Markets LLC for a secondary offering of 5,000,000 shares of common stock at $78.00 per share. The Company receives no proceeds from the sale. The offering was expected to close on August 17, 2026.
  https://www.sec.gov/Archives/edgar/data/1743881/0001140361-26-033282.txt
- 2026-08-17 · SCHEDULE 13D/A (0001140361-26-033404): SCHEDULE 13D/A - KKR Genetic Disorder L.P. — *BridgeBio Pharma, Inc. is a pharmaceutical company engaged in the development of treatments for genetic disorders.* KKR Genetic Disorder L.P. sold 5,000,000 shares of common stock of BridgeBio Pharma, Inc. at a net price of $77.415 per share through an underwriting agreement with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC, and KKR Capital Markets LLC as representatives. The offering closed on August 17, 2026. Following the offering, KKR Genetic Disorder L.P. ceased to be a beneficial owner of more than 5% of BridgeBio's common stock, making this an exit filing.
  https://www.sec.gov/Archives/edgar/data/1780408/0001140361-26-033404.txt

## Citations
- 0001140361-26-033282 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126033282
- 0001140361-26-033404 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126033404